YMAB Quote, Financials, Valuation and Earnings

Amicus Therapeutics has a net margin of -25.63% compared to Y-mAbs Therapeutics's net margin of -17.31%. Y-mAbs Therapeutics's return on equity of -30.91% beat Amicus Therapeutics's return on equity of -17.7%.

Y-mAbs Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 313.88%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 164.52%. Given that Y-mAbs Therapeutics has higher upside potential than Amicus Therapeutics, analysts believe Y-mAbs Therapeutics is more attractive than Amicus Therapeutics.

Y-mAbs Therapeutics has a beta of 0.531, which suggesting that the stock is 46.863% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.979%.

Y-mAbs Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Y-mAbs Therapeutics pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Y-mAbs Therapeutics quarterly revenues are $26.5M, which are smaller than Amicus Therapeutics quarterly revenues of $125.2M. Y-mAbs Therapeutics's net income of -$6.8M is higher than Amicus Therapeutics's net income of -$21.7M. Notably, Y-mAbs Therapeutics's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Y-mAbs Therapeutics is 1.97x versus 3.36x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Humacyte has a net margin of -25.63% compared to Y-mAbs Therapeutics's net margin of --. Y-mAbs Therapeutics's return on equity of -30.91% beat Humacyte's return on equity of --.

Y-mAbs Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 313.88%. On the other hand Humacyte has an analysts' consensus of $11.43 which suggests that it could grow by 860.38%. Given that Humacyte has higher upside potential than Y-mAbs Therapeutics, analysts believe Humacyte is more attractive than Y-mAbs Therapeutics.

Y-mAbs Therapeutics has a beta of 0.531, which suggesting that the stock is 46.863% less volatile than S&P 500. In comparison Humacyte has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Y-mAbs Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humacyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Y-mAbs Therapeutics pays -- of its earnings as a dividend. Humacyte pays out -- of its earnings as a dividend.

Y-mAbs Therapeutics quarterly revenues are $26.5M, which are larger than Humacyte quarterly revenues of --. Y-mAbs Therapeutics's net income of -$6.8M is higher than Humacyte's net income of -$39.2M. Notably, Y-mAbs Therapeutics's price-to-earnings ratio is -- while Humacyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Y-mAbs Therapeutics is 1.97x versus -- for Humacyte. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -25.63% compared to Y-mAbs Therapeutics's net margin of -49.65%. Y-mAbs Therapeutics's return on equity of -30.91% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Y-mAbs Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 313.88%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that Y-mAbs Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Y-mAbs Therapeutics is more attractive than NovaBay Pharmaceuticals.

Y-mAbs Therapeutics has a beta of 0.531, which suggesting that the stock is 46.863% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Y-mAbs Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Y-mAbs Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Y-mAbs Therapeutics quarterly revenues are $26.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Y-mAbs Therapeutics's net income of -$6.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Y-mAbs Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Y-mAbs Therapeutics is 1.97x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -25.63% compared to Y-mAbs Therapeutics's net margin of --. Y-mAbs Therapeutics's return on equity of -30.91% beat Theriva Biologics's return on equity of --.

Y-mAbs Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 313.88%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1032.29%. Given that Theriva Biologics has higher upside potential than Y-mAbs Therapeutics, analysts believe Theriva Biologics is more attractive than Y-mAbs Therapeutics.

Y-mAbs Therapeutics has a beta of 0.531, which suggesting that the stock is 46.863% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Y-mAbs Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Y-mAbs Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Y-mAbs Therapeutics quarterly revenues are $26.5M, which are larger than Theriva Biologics quarterly revenues of --. Y-mAbs Therapeutics's net income of -$6.8M is lower than Theriva Biologics's net income of -$4.4M. Notably, Y-mAbs Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Y-mAbs Therapeutics is 1.97x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.